source
- Takeda’s ADC arcotatug tavatecan shows survival benefit in phase 3 gastric cancer trialTakeda, together with Innovent Biologics, presented results from a late‑stage study of its next‑generation claudin‑18.2 antibody‑drug conjugate, arcotatug tavatecan (also known as IBI343 or TAK‑921…
- Alnylam to launch pivotal Huntington’s trial after early study shows strong huntingtin knockdownAlnylam Pharmaceuticals announced plans to move its Huntington’s disease RNAi therapy brezosiran into a pivotal, placebo‑controlled trial slated for 2027, pending regulatory alignment. The decisio…